FDA Approves ViiV Healthcare's Lexiva

Lexiva is an antiviral medication in a group of HIV medicines called protease (PRO-tee-ayz) inhibitors.

Lexiva prevents human immunodeficiency virus (HIV) cells from multiplying in your body.

Lexiva is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). It is not a cure for HIV or AIDS.

Lexiva is an HIV medication. It is in a category of HIV medicines called protease inhibitors (PIs). Lexiva prevents cells infected by HIV from producing new virus. This reduces the amount of virus in your body.

Lexiva, manufactured by ViiV Healthcare, was approved by the U.S. Food and Drug Administration on October 20, 2003.

In some parts of the world, fosamprenavir is sold under the brand name Telzir.

Lexiva must be used in combination with other HIV drugs. Along with other medications, Lexiva is often combined with low doses of Norvir (ritonavir), another protease inhibitor used to boost the amount of Lexiva in the bloodstream (which makes Lexiva more effective against HIV, including drug-resistant HIV, and easier to take).

How LEXIVA works

LEXIVA is a protease inhibitor that decreases the amount of HIV in your blood (viral load) when used with other antiretroviral medicines. It treats HIV infection by keeping the virus from making copies of itself inside the body. With less HIV, the body's immune system can work better and make more cells, called CD4 cells, which help the body fight infection.

LEXIVA is often "boosted" with Norvir

LEXIVA is often taken with another protease inhibitor called Norvir. Norvir boosts the amount of LEXIVA in the body. These medicines do not cure HIV or prevent you from giving HIV to others, but they can help control the disease.

Lexiva is an anti-HIV medication. It is in a category of HIV medicines called protease inhibitors (PIs). Lexiva prevents cells infected by HIV from producing new virus. This reduces the amount of virus in your body.

Lexiva, developed by Vertex Pharmaceuticals and GlaxoSmithKline, was approved by the U.S. Food and Drug Administration on October 20, 2003.

In some parts of the world, fosamprenavir is sold under the brand name Telzir.

Lexiva is a “prodrug” of Agenerase (amprenavir), a protease inhibitor also marketed by GlaxoSmithKline. This means that the drug must be broken down inside the body before it can become active. Doing so increases the amount of drug in the blood, while at the same time decreasing the number of pills that must be swallowed every day. Because Lexiva is easier to take and may cause less side effects than Agenerase, it is now the preferred form of amprenavir.